FDA Approves PALONOSETRON HYDROCHLORIDE — Teva Parenteral Medicines, Inc.
Teva Parenteral Medicines announced the approval of its ANDA for palonosetron hydrochloride on March 23, 2018, which expands its U.S. portfolio with an IV formulation of this key chemotherapeutic antiemetic. This strategic entry into the IV market strengthens Teva's position within the growing oncology generics sector by addressing unmet access needs for this time-sensitive treatment.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed